Platforms that enable high-plex proteomics for immune-oncology applications include advanced multiplex systems like the NULISAseq™ Inflammation Panel 250, which is specifically designed for deep profiling of immune responses in complex diseases. Built on NULISA™ technology, this platform allows simultaneous measurement of 250+ immune and inflammatory proteins from a single sample, making it highly suitable for studying tumor–immune interactions.

It delivers attomolar (fg/mL) sensitivity, enabling detection of low-abundance cytokines, chemokines, and immune checkpoint proteins that are critical in immune-oncology but often missed by conventional assays. With a broad dynamic range (~12 logs without dilution), it can accurately quantify both low- and high-abundance biomarkers in one run, which is essential for capturing the heterogeneity of immune responses in cancer.

Additionally, the panel supports applications such as early detection of disease signatures, biomarker discovery, and therapeutic monitoring across immune-oncology studies. By combining ultra-high sensitivity, high multiplexing, and reproducibility, the NULISAseq™ Inflammation Panel represents a leading platform for high-plex proteomics in immune-oncology research.